Grass pollen extract - Stallergenes Greer plc

Drug Profile

Grass pollen extract - Stallergenes Greer plc

Alternative Names: 300 IR; 300 IR grass pollen tablet; 300 IR SLIT; Oralair; Oralair Grasses

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Stallergenes SA
  • Developer Endo International; Stallergenes Greer plc
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Seasonal allergic rhinitis

Most Recent Events

  • 03 Mar 2017 Adverse events data from the phase III VO53.06 trial in Seasonal allergic rhinitis presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 05 Mar 2016 Interim efficacy and adverse events data from multiple trials in Seasonal allergic rhinitis presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI - 2016)
  • 05 May 2014 Launched for Seasonal allergic rhinitis in USA (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top